---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-082477"
form_type: "8-K"
ticker: "TKNO"
cik: "0001850902"
company_name: "Alpha Teknova, Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:39:34.863570+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alpha Teknova reports Q2 2024 rev $9.4-9.6M, reaffirms FY guidance $35-38M

## Summary
- Q2 2024 total revenue $9.4-9.6M, down 17-18% YoY but up 7-9% adjusting for large prior-year order.
- FY 2024 revenue guidance reaffirmed at $35-38M; free cash outflow <$18M.
- Headcount reduced >40% from Q2 2022 peak to 169; cash used in Q2 was $3.0-3.4M.
- Clinical Solutions customers grew from 34 to 43; Lab Essentials customers from 2,829 to 2,913.
- No single direct customer >$1M YTD; full Q2 results expected August 13, 2024.

## SEC filing metadata
- accession: 0000950170-24-082477
- form_type: 8-K
- ticker: TKNO
- cik: 0001850902
- company_name: Alpha Teknova, Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850902/000095017024082477/0000950170-24-082477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850902/000095017024082477/tkno-20240709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-082477
- JSON: https://secwatch.observer/filing/0000950170-24-082477.json
- Plain text: https://secwatch.observer/filing/0000950170-24-082477.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.